Boston Scientific CorpBSX

Boston Scientific’s latest 10-Q, filed on 7 May 2026 for the quarter ended 31 March 2026, shows revenue of $5.20 billion, operating income of $1.10 billion, and diluted EPS of $0.90 on 1.50 billion shares. The balance sheet carries $44.35 billion of assets against $25.86 billion of shareholders’ equity, with $1.45 billion of cash and equivalents and $3.12 billion of inventory-up $177 million from the prior quarter. Operating cash flow was $348 million, while capex gobbled $177 million, leaving free cash flow at roughly break-even for the period. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/885725/000088572526000011/0000885725-26-000011-index.htm)

Boston Scientific sells medical devices used in cardiac rhythm management, endoscopy, urology, and surgery. Customers-hospitals, clinics, and surgery centres-order products through multiple channels: online storefront, EDI, phone, fax, or email. The company’s customer-care line, still fielding calls at (888) 272-1001, describes itself as a support hub, while a product-security page reassures clinicians that Boston Scientific has “built a strong product security program.” (source: Order products, https://www.bostonscientific.com/en-US/customer-service/ordering.html; Customer support and services, https://www.bostonscientific.com/en-US/customer-service.html; Product Security, https://www.bostonscientific.com/en-US/customer-service/product-security.html)

Boston Scientific’s employee “Everyone Makes an Impact” event is billed as a reminder that 48,000-plus staff touch the lives of 37 million patients each year. The filing maths tell a quieter story: 37 million divided by 365 days equals about 101,370 procedures a day, or roughly 506,850 devices in circulation at any moment if the average implant lasts five years. Maintaining that flow requires a $3.12 billion inventory pile that grew by $177 million this quarter, while the cash engine produced only $348 million in operating cash-leaving precious little cushion once $177 million was sunk into capex. (source: At Boston Scientific, product quality is a personal mandate, https://news.bostonscientific.com/at-boston-scientific-product-quality-is-a-personal-mandate; 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/885725/000088572526000011/0000885725-26-000011-index.htm)

The company’s filing cadence is healthy: 10-Qs, 8-Ks, an annual 11-K, and a parade of exhibits on SEC EDGAR. The 8-K filed on 2 July 2026 is a standard notice about temporary employees and eligibility for the employee plan, while the 11-K filed on 24 June 2026 quietly confirms that eligibility under the plan is the corporate equivalent of a participation trophy-nice optics, but not the engine of cash generation. The SEC submissions JSON shows the company’s filings stack, yet none of the documents filed in the last sixty days disclose any material change in guidance or segment mix. (source: BSX 4 (2026-07-02), https://www.sec.gov/Archives/edgar/data/885725/000122520826006362/xslF345X06/doc4.xml; BSX 11-K (2026-06-24), https://www.sec.gov/Archives/edgar/data/885725/000088572526000046/bsc-20260624.htm; SEC submissions JSON, https://data.sec.gov/submissions/CIK0000885725.json)

If you want a live chart route, the SEC filings point to the company’s profile on the official EDGAR index. The site lists every submission but does not supply price data or technical levels; the renderer will overlay the chart from your local source. No trading levels, moving averages, or support/resistance bands are included here because the evidence does not supply them. (source: BSX SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=885725)

Boston Scientific’s customer-ordering page still advertises fax and email options alongside an online portal, a menu that looks more like an inventory warehouse than a 2026 digital platform. Yet the company insists its product-security program is “strong,” a word whose meaning in regulatory filings usually trails a comma and the phrase “material weakness.” The gap between the polished slide deck and the actual numbers-$5.20 billion in revenue but only $1.45 billion in cash, $3.12 billion in inventory, and $0.90 EPS-tells the clearer story. (source: Order products, https://www.bostonscientific.com/en-US/customer-service/ordering.html; Product Security, https://www.bostonscientific.com/en-US/customer-service/product-security.html; 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/885725/000088572526000011/0000885725-26-000011-index.htm)